Company intelligence / Profile preview

Nextrans

United States

Ownership: Private
Development stage: Other

Overview

Nextran developed genetically modified pig organs for xenotransplantation. In 1995, it received FDA clearance to begin the industry's first human clinical safety trials using transgenic pig livers as a temporary organ support system until a donor organ was available or the patient's own liver regenerated.

Therapeutic areas: Rare Diseases
Modalities: Genetically modified organs (xenotransplantation)
Industry: Implantable Medical Devices

Partnerships

DNX Corporation (original joint venture partner)Duke University Medical Center

Beyond the preview

Go deeper on Nextrans.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nextrans.

Explore the full profile